Legal Representation
Attorney
Eva Gullick Frongello
USPTO Deadlines
Next Deadline
1374 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-04-25)
Due Date
April 25, 2029
Grace Period Ends
October 25, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 8, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| May 8, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 8, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 8, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 8, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 25, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 25, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 6, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Mar 6, 2023 | LOPR | P | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | Loading... |
| Mar 6, 2023 | ATRV | O | ATTORNEY REVIEW COMPLETED | Loading... |
| Mar 1, 2023 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Jan 18, 2023 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Dec 20, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 20, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 15, 2022 | LOPT | I | LETTER OF PROTEST EVIDENCE FORWARDED | Loading... |
| Nov 30, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 17, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 2, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 2, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 2, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 12, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 12, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 17, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 13, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno
First Use Anywhere:
Feb 11, 2008
First Use in Commerce:
Feb 11, 2008
Class 005
pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use
First Use Anywhere:
Feb 25, 2016
First Use in Commerce:
Feb 25, 2016
Class 042
research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
First Use Anywhere:
Feb 11, 2008
First Use in Commerce:
Feb 11, 2008
Class 044
Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer
First Use Anywhere:
Feb 25, 2016
First Use in Commerce:
Feb 25, 2016
Classification
International Classes
001
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOSCIENCES"